SCHEMBL6496586

SCHEMBL6496586

Cc1c(NC(=O)O)ccc2[nH]c(=O)oc(=O)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 1/20 0.38
NOS1 P29475 3/20 0.37
ALPL P05186 5/20 0.36
ALPI P09923 4/20 0.36
ALPG P10696 3/20 0.36
POLB P06746 2/20 0.36
NOS2 P35228 2/20 0.36
CTRB1 P17538 2/20 0.36
F2 P00734 1/20 0.36
CFD P00746 1/20 0.36
PDGFRA P16234 1/20 0.36
MAPK8 P45983 1/20 0.36
CDK5 Q00535 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NOS3 P29474 1/20 0.34
ELANE P08246 1/20 0.34
ESR2 Q92731 2/20 0.33
MAOA P21397 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6508140 0.73 ESR1 (0.44) CREBBPNOS1NOS2F2CFD
SCHEMBL6806690 0.71 NOS1 (0.33) CREBBPNOS1NOS2F2CFD
SCHEMBL619937 0.66 F2 (0.52) NOS1NOS2F2CFDPDGFRA
SCHEMBL6499021 0.65 MAPT (0.43) F2CFDMEN1KMT2AKDM4E
SCHEMBL4504381 0.65 CREBBP (0.47) CREBBPF2CFDKMT2AKDM4E
SCHEMBL4490244 0.65 AR (0.45) CREBBPNOS1POLBNOS2F2
SCHEMBL21460047 0.65 NOS1 (0.56) CREBBPNOS1ALPLALPIALPG
SCHEMBL4509421 0.64 F2 (0.49) NOS1POLBF2CFDPDGFRA
SCHEMBL3981208 0.64 F2 (0.41) CREBBPNOS1NOS2F2CFD
SCHEMBL10756217 0.63 F2 (0.43) CREBBPNOS1NOS2F2CFD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032793-A1 2-amino-benzoxazinones for the treatment of viral infections G.D. SEARLE & CO. (US) 2005-02-10 US disclosed
EP-0828721-B1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS SEARLE & CO (US) 2001-11-14 EP disclosed
EP-1122245-A2 2-Amino-benzoxazinones for the treatment of viral infections G.D. Searle & Co. (US) 2001-08-08 EP disclosed
US-5985872-A THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION G.D. SEARLE & CO. (US) 1999-11-16 US disclosed
CN-1190963-A 2-amino-benzoxanones for the treatment of viral infections SEARLE & CO (US) 1998-08-19 CN disclosed
WO-1996037485-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1996-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032793-A1 2-amino-benzoxazinones for the treatment of viral infections IFNAR1, IL4I1, ACE2 CREBBP 416/4885NOS1 4366/4885ALPL 4572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.